Synthesis and biological evaluation of stilbene-based pure estrogen antagonists

Bioorg Med Chem Lett. 2004 Sep 20;14(18):4659-63. doi: 10.1016/j.bmcl.2004.06.098.

Abstract

Replacement of one of the ethyl substituents in diethylstilbestrol by side chains with functional groups converted this potent estrogen into pure antiestrogens with the potential for the treatment of breast cancer. These agents completely suppressed estrogen receptor-mediated gene activation and inhibited the growth of estrogen-sensitive MCF-7 breast cancer cells in submicromolar concentrations. The most potent derivative displayed similar activity as fulvestrant (ICI 182,780) in vitro and in the mouse uterine weight test. Obviously, the stilbene structure can act as a substitute for estradiol in the development of pure estrogen antagonists.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Breast Neoplasms
  • Cell Line, Tumor
  • Estradiol / analogs & derivatives*
  • Estradiol / pharmacology
  • Estrogen Antagonists / chemical synthesis*
  • Estrogen Antagonists / chemistry
  • Estrogen Antagonists / pharmacology
  • Female
  • Fulvestrant
  • Humans
  • Mice
  • Organ Size / drug effects
  • Stilbenes / chemical synthesis*
  • Stilbenes / chemistry
  • Stilbenes / pharmacology
  • Structure-Activity Relationship
  • Uterus / drug effects

Substances

  • Antineoplastic Agents
  • Estrogen Antagonists
  • Stilbenes
  • Fulvestrant
  • Estradiol